TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pain Outcomes of Non-opioid vs. Opioid Analgesia for Kidney Stone Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women age\>18 years old~* Presence of renal or ureteral stones suitable for ureteroscopy or percutaneous nephrolithotomy.~* Uncomplicated ureteroscopy or percutaneous nephrolithotomy~Exclusion Criteria:~* Pregnant/Breastfeeding/Possibly Pregnant Patients~* Pediatric Patients~* Sensitive or Allergic to Opioids, Ketorolac, or Acetaminophen~* Significant Renal Disease~* Peptic Ulcer Disease~* Chronic Pain and recovering opiate use~* Inability to complete questionnaires~* Non-mobile patients~* Patients on methadone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-Opioid Analgesia (Type: EXPERIMENTAL): Ketorolac - Oral; 10 mg tablet: 1 tablet every 6 hours, or as needed. (20 tablets prescribed).~Acetaminophen - Oral; patient directed as needed. Not prescribed.~Ketorolac and Acetaminophen administered post surgery to compare pain outcomes to that of Percocet.
- Opioid Analgesia (Type: ACTIVE_COMPARATOR): Percocet - Oral; 5 mg tablet: 1 tablet every 4-6 hours, or as needed. (10 tablets prescribed).~Percocet administered post surgery to compare pain outcomes to that of the non-opioid analgesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients will be infants of both sexes aged 12 ± 3 months with chronic renal insufficiency and growth retardation.~* To be included in the trial, patients must meet all of the following inclusion criteria a.)-c.):~* a.) Male or female infants with a chronological age of 12 ± 3 months~* b.) Chronic renal insufficiency with Glomerular Filtration Rate less than 60 ml/min./1.73m2, according to the method used routinely in each participating center~* c.) Growth retardation documented at the start of the trial, according to the following criteria: Length less than -2 SDS by chronological age and sex and linear growth velocity \<P50 according to the Hernández standards and to Lubchenko in the case of infants born prematurely (\<37 weeks)~* Conservative treatment or chronic peritoneal dialysis~* Euthyroid~* The parent or guardian must give informed consent to the child's participation in the study before any trial related activities. Trial related activities are any procedures that would not have been performed during the normal management of the subject~* Optimal nutritional management criteria met~* Appropriate metabolic control for severe hyperparathyroidism, hydroelectrolyte balance, acid-base balance and calcium-phosphorus balance~Exclusion Criteria:~* Any primary endocrinological disorder and severe renal osteodystrophy.Other causes, apart from CRI, giving rise to growth retardation.Hydrocephalus.~* Known or suspected allergy to the trial product or related products.~* Treatment with corticosteroids within the last six months.~* Renal disease due to the Fanconi syndrome or to oxalosis (except if not under dialysis).~* Known or suspected malignancy.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 15 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Sickle Cell Disease (HbSS, HbSC, HbSβ⁰-thalassemia, or HbSβ⁺-thalassemia)~* If receiving hydroxyurea or erythropoietin, treatment must have been prescribed for at least 6 months, with the dose stable for at least 3 months~* Between 2 and 10 sickle cell-related pain crises in the past 12 months~Key Exclusion Criteria:~* On a chronic transfusion program or planning on exchange transfusion during the study~* Hemoglobin \<4.0 g/dL~* Planned initiation, termination, or dose alteration of hydroxyurea during the study~* Receiving chronic anticoagulation therapy (e.g. warfarin, heparin) other than aspirin

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- High-dose SelG1 (Selg1 5.0 mg/kg) (Type: EXPERIMENTAL): IV Infusion, once every 4 weeks through Week 50
- Low-dose SelG1 (Selg1 2.5 mg/kg) (Type: EXPERIMENTAL): IV Infusion, once every 4 weeks through Week 50
- Placebo (Type: PLACEBO_COMPARATOR): IV Infusion, once every 4 weeks through Week 50

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Testosterone on Mood and Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 50 or older~* Total Testosterone \<=280 ng/dl~* Subsyndromal depressive disorder: either dysthymia or minor depression (per DSM IV and DSM IV appendix)~Exclusion Criteria:~* PSA \>=3.0~* Klinefelter's syndrome~* Prostate or breast cancer~* Hospitalized in the past month~* Obstructive BPH~* Current testosterone treatment~* Schizophrenia, bipolar disorder, dementia~* Treatment with antipsychotics or benzodiazepines~* Alcohol dependence or other substance dependence~* Suicidal or psychotic symptoms

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Performance status ECOG-WHO ≤ 1~* histologically proved and unresectable locally advanced or metastatic squamous cell anal carcinoma~* patient eligible to DCF regimen~* signed written informed consent~Exclusion Criteria:~* known hypersensitivity or contraindication to any of the study drugs (docetaxel, cisplatin, 5-fluorouracil).~* previous chemotherapy for metastatic disease~* previous chemotherapy by paclitaxel, docetaxel or navelbine~* previous chemotherapy by cisplatin, except of concomitant radiotherapy~* SIDA~* clinically significant cardiac disease~* other malignancy within the last 3 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.~* simultaneous participation in another clinical study~* pregnancy, breast-feeding or absence of adequate contraception for fertile patients~* patient with any medical or psychiatric condition or disease which would make the patient inappropriate for entry into this study.~* patient under guardianship, curator or under the protection of justice.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DCF regimen (Type: EXPERIMENTAL): docetaxel 75 mg/m2 day, Cisplatin75 mg/m2 and 5Fluorouracil at 750 mg/m2/day for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intravenous Dexamethasone on Postoperative Caudal Analgesia in Pediatric Orchiopexy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients scheduled for elective day-case orchiopexy.~Exclusion Criteria:~* Infants or children with history of steroid allergy, renal, hepatic disease, or contraindication for caudal analgesia.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent~* 18 years ≤ age ≤ 35 years on the day of the first visit~* 22.0 ≤ BMI ≤ 28.0 kg/m2~* (History of) good physical and mental health as determined by history taking, physical and laboratory examinations and ECG.~* fasting glucose level of \< 5.6 mmol/L, in addition to a glucose level of \< 7.8 mmol/L at 2 hours after intake of 75 g glucose (OGTT).~* able to keep a normal day and night rhythm during the trial period (i.e. no shift work)~Exclusion Criteria:~* history or presence of a medical disorder~* use of drugs, except for incidental (non-opioid) analgesic agents~* first degree relative with T2DM~* performing intensive physical activity \> 1x/week~* an allergic or anaphylactic reaction to prednisolone treatment in the past~* clinically relevant history or presence of any medical disorder, which are mentioned in the Summary of Product Characteristics (SPC) as contraindication for the use of prednisolone~* glucocorticosteroid use during the last three months prior to the first dose~* participation in an investigational drug trial within 90 days prior to the first dose~* donation of blood (\> 100 mL) within 90 days prior to the first dose~* history of or current abuse of drugs or alcohol (\>14 U/week)~* smoking~* use of grapefruit products during the study period~* recent changes in weight and/or physical activity~* serious mental impairment or language problems i.e. preventing to understand the study protocol/aim

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 60 years and older with de novo AML and non-poor cytogenetic features.~* Patients with no unfavourable cytogenetic (based on GOELAMS-BGMT criteria)~* Performance status and Sorror score \< 3 .~* Signed and dated informed consent.~Exclusion Criteria:~* Acute promyelocytic leukemia.~* Patients with myeloproliferative syndromes prior to diagnosis of AML.~* Patients who previously had myelodysplastic syndrome.~* Positive serology for HIV.~* Patients with unfavourable cytogenetic~* Patients with an isolated medullary extra localization of their disease

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients will be treated by adding lomustine to chemotherapy
- 2 (Type: NO_INTERVENTION): Patients will be treated without adding lomustine to chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients who are diagnosed as gastric cancer.~* No prior treatment for gastric cancer.~* Negative or unknown for HER2 testing.~* ECOG performance status of 0 or 1.~Key Exclusion Criteria:~* Unmanageable diarrhea.~* Current peripheral sensory neuropathy or paresthesia.~* Pregnant or lactating female.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-118/Oxaliplatin (Type: EXPERIMENTAL): TAS-118 plus Oxaliplatin
- S-1/Cisplatin (Type: ACTIVE_COMPARATOR): S-1 plus Cisplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Cohort number 1:Organ transplant patients who were vaccinated and serum sample drawn at baseline.~Cohort number 2: Staff members who were vaccinated and serum sample drawn at baseline.~Exclusion Criteria:~Cohort number 1: Organ transplant patients who were vaccinated and no serum sample drawn at baseline.~Cohort number 2: Staff members who were vaccinated and no serum sample drawn at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- organ transplant patients (Type: None): None
- healthy controls (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Dysrhythmias on the Cardiac Intensive Care Unit - Does Maintenance of High-normal Serum Potassium Levels Matter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to have isolated CABG surgery~* Patient in sinus rhythm~Exclusion Criteria:~* Age less than 18 years~* Previous history of Atrial Fibrillation, Atrial Flutter and/or Atrial Tachyarrhythmia~* Pre-operative high-degree atrioventricular (AV) block (defined as Mobitz type 2 second degree AV block or complete heart block)~* Pre-operative serum \[K+\] greater than 5.5 mEq/L~* Current/previous use of medication for the purposes of cardiac rhythm management~* Dialysis-dependent end-stage renal failure~* Concurrent patient involvement in another clinical trial assessing cardiac rhythm post-operative interventions~* Unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Relaxed control (Type: EXPERIMENTAL): Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below 3.6 mEq/L.
- Tight control (Type: ACTIVE_COMPARATOR): Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Dexamethasone to Increase the Analgesic Duration of Interscalene Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Elective shoulder arthroscopy under ropivacaine single-shot interscalene brachial plexus block anesthesia (rotator cuff repair and shoulder decompression)~* ASA I-III~* Age 18-80 years old~Exclusion Criteria:~* Any contraindication to interscalene brachial plexus block anesthesia~* Interscalene brachial plexus block failure~* Known local anesthetics allergy~* Dexamethasone allergy or intolerance~* Any contraindication to acetaminophen~* Any contraindication to morphine or hydromorphone~* Brachial plexus neuropathies~* Chronic pain syndrome other than shoulder pain~* Routine use of opioid medication~* Routine use of systemic corticosteroid~* Pregnancy~* Weight below 50 kilograms~* Incapability to understand a numeric verbal pain scale~* Incapability to consent~* Patient refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone 10 mg intravenous (Type: EXPERIMENTAL): Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
- Dexamethasone 4 mg intravenous (Type: EXPERIMENTAL): Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
- Normal Saline 20 mL intravenous (Type: PLACEBO_COMPARATOR): Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Paracetamol on the Common Cold

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of the common cold of no more than 120 hours duration~* Self-rating congestion of at least moderate severity~* Suffering from at least four symptoms of common cold or flu

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paracetamol hot drink (Type: ACTIVE_COMPARATOR): Hot drink containing paracetamol
- Paracetamol tablets (Type: ACTIVE_COMPARATOR): Paracetamol tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Light Therapy on Circadian Rhythms, Sleep, and Mood in Postpartum Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Within 6 months postpartum~* Meet DSM-V diagnostic criteria for MDD~* Score ≥ 20 on the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder version (SIGH-SAD).~Exclusion Criteria:~* current diagnosis of bipolar disorder, posttraumatic stress disorder, schizophrenia or psychosis, dissociative disorders, eating disorder, obsessive-compulsive disorder, somatic symptom and related disorders, substance use disorder, panic disorder, agoraphobia per DSM-V~* past history of mania/hypomania,~* chronic medical conditions associated with depression (e.g., thyroid conditions)~* ocular or retinal pathology~* history of seizures or epilepsy~* color blindness~* Lupus~* currently taking an antibiotic, medication that contains hydrochlorothiazide, or isotretinoin (Accutane).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Light Therapy (Type: EXPERIMENTAL): Participants will use commercially-available light therapy glasses (Re-Timer) daily for 60 minutes for five weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have body weight at least 40 kilogram (kg)~* Patients with recurrent mature B-cell neoplasms as defined according to WHO classification, including small lymphocytic lymphoma/ chronic lymphocytic leukemia, mantle cell lymphoma, and follicular lymphoma~* Have measurable disease \[for Non-Hodgkin's Lymphoma (NHL) bi-dimensional disease more than or equal to 2 cm diameter in at least one dimension and for chronic lymphocytic leukemia more than or equal to 5000 leukemia cells/cubic mm\]~* Have failed more than or equal to 1 previous treatment and no standard therapy is available~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Patients with plasma cell neoplasm as defined according to WHO classification~* Patients who have received prior allogeneic hematopoietic stem cell transplant~* Patients who have received immunotherapy, chemotherapy, radiotherapy or experimental therapy within 4 weeks before first day of study medication~* Past history of major surgery within 4 weeks before the first day of study medication~* Patients with central nervous system involvement

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCI-32765 (Type: EXPERIMENTAL): Patients will receive oral doses of PCI-32765 in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be given before administration of daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete